Stocktoria
ProMIS Neurosciences Inc. PMN
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2017-04-03
ProMIS Neurosciences Inc. financials (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| R&D expense | $33.4M | $10.6M | $7.9M | $16.1M | $4.6M |
| Operating income | -$40.2M | -$16.8M | -$14.3M | -$23.4M | -$8.3M |
| Income tax | — | $0 | $0 | $0 | — |
| Net income | -$39.7M | $2.8M | -$13.2M | -$18.1M | -$9.8M |
| EPS (diluted) | $-22.61 | $2.63 | $-1.07 | $-2.41 | $-1.69 |
| Operating cash flow | -$28.1M | -$27.2M | -$10.8M | -$17.0M | -$9.3M |
| Free cash flow | — | — | — | -$17.0M | -$9.3M |
| Cash & equivalents | $6.1M | $13.3M | $12.6M | $5.9M | $16.9M |
| Total assets | $9.2M | $18.9M | $13.6M | $6.9M | $17.7M |
| Total liabilities | $10.4M | $2.4M | $9.9M | $8.3M | $12.1M |
| Shareholders' equity | -$1.3M | $16.5M | $3.8M | -$1.3M | $5.7M |
Source: SEC EDGAR filings · CIK 0001374339 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.